Le Lézard
Classified in: Health
Subject: PER

Fresenius Medical Care North America Appoints Angela McClure to Chief Experience Officer


WALTHAM, Mass., March 20, 2018 /PRNewswire/ -- Fresenius Medical Care North America (FMCNA), the country's leading provider of kidney care products and services, announces the appointment of Angela McClure to the newly created role of chief experience officer (CXO). In her new role, McClure will report directly to Chief Executive Officer Bill Valle and joins the Fresenius Medical Care North America Leadership Team. As CXO, McClure will lead the development of an experience strategy across all audiences, including employees, patients and their families, partners and physicians.

McClure will drive the enterprise-wide effort to embed customer experience in all employees, from leadership to front-line staff. One component of McClure's new position will be to work closely with the company's teams already engaged in enhancing its experience efforts, from patient care to products to human resources. She will assemble a cross-functional and cross-business team to enhance experience efforts and elevate the company's commitment to being world class and setting a standard for which others in healthcare are judged.

"Across our organization, we always strive to continuously improve the overall experience we provide to employees, patients and their families, partners, physicians and customers ? but we want to do more," said Bill Valle, chief executive officer of Fresenius Medical Care North America. "This important work supports stronger engagement, which will lead to better quality and higher performance. Angela McClure is leading the effort to foster a culture of service excellence across the organization. This focused and dedicated leadership change will accelerate improvements in our Net Promoter Scores and Employee Net Promoter Scores that we have achieved for three successive years."

With more than 2,400 dialysis facilities across the country, Fresenius Medical Care North America has gained a deep understanding of patient insights and what matters most to patients. To enrich the patient experience that is delivered both today and in the future, McClure and her team have partnered with a leading consultancy with expertise in helping premier healthcare organizations deliver superior care through patient insights.

"In this new role, I look forward to building on the existing foundation of highly engaged, collaborative employees to provide the best and most personalized care to our patients," said Angela McClure, chief experience officer, Fresenius Medical Care North America. "To live out our company's mission, we must ensure that our employees, customers and patients are treated and treat one another with respect, empathy and compassion and that we are doing this through collaboration and coordination. This is our promise and our differentiator."

The Fresenius Medical Care North America cultural evolution began a few years ago with the implementation of the Leading with Values program, led by McClure. Since the program's inception, more than 6,000 company leaders have participated in the program and carry out its philosophy on an ongoing basis.

McClure previously served as senior vice president of human resources for Fresenius Kidney Care, Azura, Physician Practice Services and Spectra Laboratories. While supporting Fresenius Kidney Care, McClure's employee engagement efforts ? as part of a unified strategy with the customer experience team ? helped the division realize marked improvements in employee engagement, recognition and retention, and patient experience.

About Fresenius Medical Care North America
Fresenius Medical Care North America is the premier healthcare company focused on providing the highest quality care to people with renal and other chronic conditions. Through its industry-leading network of dialysis facilities, outpatient cardiac and vascular labs, and urgent care centers, as well as the country's largest practice of hospitalist and post-acute providers, Fresenius Medical Care North America provides coordinated health care services at pivotal care points for hundreds of thousands of chronically ill customers throughout the continent. As the world's largest fully integrated renal company, it offers specialty pharmacy and laboratory services, and manufactures and distributes the most comprehensive line of dialysis equipment, disposable products and renal pharmaceuticals. For more information, visit the FMCNA website at https://fmcna.com.

Media Contact:
Jane Hauser
Fresenius Medical Care North America
781-699-4757
[email protected]

SOURCE Fresenius Medical Care North America


These press releases may also interest you

at 07:10
Can-Fite BioPharma Ltd. , a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced financial results and clinical updates for the twelve months ended...

at 07:10
Kelonia Therapeutics, a biotech company revolutionizing in vivo gene delivery, today announced the appointments of global leaders in cell therapy and drug development, Kristen Hege, M.D., and Mathai Mammen, M.D., Ph.D., to its board of directors....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the clinical development plan intended to enable...

at 07:05
Mythic Therapeutics, a clinical-stage biotechnology company committed to the development of next-generation antibody-drug conjugate (ADC) therapies for the treatment of a wide range of cancers, announced that George Eliades, Ph.D., has joined the...

at 07:05
Seres Therapeutics, Inc. ("Seres" or the "Company"), a leading microbiome therapeutics company, today announced that on March 25, 2024, the Compensation and Talent Committee of Seres' board of directors granted inducement equity grants covering an...

at 07:05
Gilead Sciences, Inc. and Xilio Therapeutics, Inc. today announced an exclusive license agreement to develop and commercialize Xilio's Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company...



News published on and distributed by: